...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nuclearmedicine >CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence: Factors influencing the area under the ROC curve [CA15.3-Messungen zur Unterscheidung positiver und negativer FDG-PET/CT-befunde bei mammakarzinomrezidiven: Faktoren, die einen Einfluss auf die fl?che unterhalb der ROC-Kurve haben]
【24h】

CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence: Factors influencing the area under the ROC curve [CA15.3-Messungen zur Unterscheidung positiver und negativer FDG-PET/CT-befunde bei mammakarzinomrezidiven: Faktoren, die einen Einfluss auf die fl?che unterhalb der ROC-Kurve haben]

机译：CA 15.3在乳腺癌复发中将FDG PET / CT阳性与阴性结果分离的测量：影响ROC曲线下面积的因素[CA15.3在乳腺癌复发中对阳性和阴性FDG PET / CT结果进行区分的因素：对ROC曲线下方的区域有影响]

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In breast cancer CA 15.3 is considered the tumour marker of choice. CA 15.3 is directly related to the disease extent and to hormone status (estrogen receptor ER+/ ER-, progesterone receptor PR+/PR-). This study was designed to assess the impact of disease extent, hormone receptor and HER2-status, and circulating blood volume on the area-under the ROC-curve of CA 15.3 to separate FDG PET positive from negative findings. Patients, methods: We retrospectively evaluated 379 FDG PET/CT examinations performed in 80 patients with breast cancer. Blood volumes were derived using the formulas by Nadler and multiplied by their corresponding CA 15.3 measurement. Results: ROC-curve analysis revealed an AUC of 0.695 (p = 0.0001) for CA 15.3 to separate FDG PET positive from negative findings. AUC measurements to separate normal scan findings from loco-regional disease and metastatic disease were 0.527 (p = 0.587) and 0.732 (p = 0.0001), respectively. AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in ER+ and ER- patients, were respectively 0.772 (p = 0.0001) and 0.596 (p = 0.143). AUC measurements for CA 15.3 to separate positive from negative FDG PET findings, in PR+ and PR- patients, were respectively 0.675 (p = 0.0001) and 0.694 (p = 0.0001). In HER2-positive and -negative patients, the AUC measurements were respectively 0.594 (p = 0.178) and 0.701 (p = 0.0001) to separate positive from negative FDG PET findings. Conclusion: The AUC for CA 15.3 measurements to separate FDG PET positive from negative findings in breast cancer patients with suspected recurrence proved to be directly related to the extent of the recurrent disease and hormone receptor status and inversely related to HER2-status. Correcting CA 15.3 measurements for blood volumes did not impact the AUC.
机译：在乳腺癌中，CA 15.3被认为是选择的肿瘤标志物。 CA 15.3与疾病程度和激素状态（雌激素受体ER + / ER-，孕激素受体PR + / PR-）直接相关。本研究旨在评估疾病程度，激素受体和HER2状态以及循环血量对CA 15.3的ROC曲线下方区域的影响，以将FDG PET阳性与阴性结果分开。患者，方法：我们回顾性评估了80名乳腺癌患者中进行的379次FDG PET / CT检查。使用纳德勒的公式得出血容量，并乘以其相应的CA 15.3测量值。结果：ROC曲线分析显示CA 15.3的AUC为0.695（p = 0.0001），从而将FDG PET阳性与阴性结果分开。将正常扫描结果与局部区域疾病和转移性疾病分开的AUC测量值分别为0.527（p = 0.587）和0.732（p = 0.0001）。在ER +和ER-患者中，CA 15.3的AUC测量值将阳性和阴性FDG PET结果分开，分别为0.772（p = 0.0001）和0.596（p = 0.143）。在PR +和PR-患者中，CA 15.3的AUC测量值将FDG PET阳性结果与阴性结果分开，分别为0.675（p = 0.0001）和0.694（p = 0.0001）。在HER2阳性和阴性患者中，AUC分别为0.594（p = 0.178）和0.701（p = 0.0001），以区分阳性和阴性FDG PET结果。结论：CA 15.3测量的AUC可将疑似复发的乳腺癌患者的FDG PET阳性与阴性结果区分开来，这被证明与复发疾病的程度和激素受体状态直接相关，而与HER2状态呈负相关。校正CA 15.3的血容量测量值不会影响AUC。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号